A technology validated by clinical study.
A technology validated by clinical study. en-TEAR technology was validated in a clinical study focused on eye health, demonstrating our ability to support ocular surface health through gut microbiome modulation.
Study design
- 018-week intervention period.
- 02Patients with dry eye.
- 03Enbiosis Formulation® targeting the gut-eye axis.
Endpoints
- Schirmer test (mm)
- DEQ-5 (Dry Eye Questionnaire-5)
- OSDI (Ocular Surface Disease Index)
- TBUT (Tear Breakup Time)
- Microbiome analysis
Results
Higher tear production compared with standard care, maintained at 16-week follow-up alongside favorable changes in the microbiome profile.
0%
Tear production (en-TEAR)
≈40% standard treatment
+0 mm
Tear production (en-TEAR)
+2-3 mm standard treatment
0 weeks
Improvement maintained at follow-up
with favorable microbiome changes
Pilot study (n=20). The manuscript is currently under journal review, with publication expected in the first half of 2026.
Everything we build starts with evidence.
Clinical evidence is where everything we do begins. Our values as a company, the technology we build and the direction we take are all grounded in it. We run and publish peer-reviewed research, turn what we learn into new methods and formulations, and work to make them accessible to everyone who needs them. The four publications below are the foundation en-TEAR stands on.
Peer-reviewed publications
- 01
Journal of Clinical Medicine (2022): AI-Assisted Personalised Microbiome Modulation by Diet in Functional Constipation (RCT).
- 02
Gut Microbes (2022): Artificial intelligence-based personalised diet, a pilot clinical study for IBS.
- 03
American Journal of Gastroenterology (2024): Multicenter RCT of Microbiome-Based AI-Assisted Personalised Diet vs Low-FODMAP for IBS.
- 04
Biomedical Signal Processing and Control (2025): Deep learning-enhanced wellness scores, a population-level study on gut microbiome profiling.
Independent recognition
Gold Medal winner among 256 high-potential technology ventures from Europe, Turkey, and Israel.
This is just the beginning.
We model biological interactions across multiple systems of the body using Digital Twin and AI. en-TEAR is the first step; new clinical formulations are next.
Eye health
en-TEAR
A clinically validated formulation targeting the gut-eye axis. It supports tear production and tear film stability, reduces ocular surface inflammation, and helps relieve dry eye symptoms.
Clinically validated.
Metabolism
en-JOY&HEALTH
Targets gut microbiome pathways to support metabolic health, glycemic control, and insulin sensitivity; reduces systemic inflammation.
Clinical research ongoing.
Skin health
en-CLEAR
Targets the gut-skin axis to support skin barrier function and reduce psoriasis-related systemic inflammation.
Clinical research ongoing.
Men's health
en-MASCULINE
Targets the gut-prostate axis to support pelvic health and hormonal balance in men. Formulated to address key biological pathways related to pelvic pain and testosterone levels.
Clinical research ongoing.
Ready to bring en-TEAR to your market?
We partner with clinicians, pharmacies, and distributors who share our commitment to evidence-based care. Let's start the conversation.